What is Bioject Medical Technologies Price-to-Operating-Cash-Flow?
As of today (2024-05-16), Bioject Medical Technologies's share price is $0.0001.
Bioject Medical Technologies's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Sep. 2011 was $0.03. Hence, Bioject Medical Technologies's Price-to-Operating-Cash-Flow Ratio for today is 0.00.
The historical rank and industry rank for Bioject Medical Technologies's Price-to-Operating-Cash-Flow or its related term are showing as below:
Bioject Medical Technologies's Cash Flow from Operations per share for the
three
months ended in Sep. 2011 was $0.00.
Its Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Sep. 2011 was $0.03.
Bioject Medical Technologies Price-to-Operating-Cash-Flow Historical Data
The historical data trend for Bioject Medical Technologies's Price-to-Operating-Cash-Flow can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bioject Medical Technologies Price-to-Operating-Cash-Flow Chart
|
Bioject Medical Technologies Annual Data
|
|
Trend |
Mar01 |
Mar02 |
Dec03 |
Dec04 |
Dec05 |
Dec06 |
Dec07 |
Dec08 |
Dec09 |
Dec10 |
| Price-to-Operating-Cash-Flow |
|
Get a 7-Day Free Trial
|
|
|
- |
- |
7.00 |
13.00 |
- |
|
Bioject Medical Technologies Quarterly Data
|
|
Dec06 |
Mar07 |
Jun07 |
Sep07 |
Dec07 |
Mar08 |
Jun08 |
Sep08 |
Dec08 |
Mar09 |
Jun09 |
Sep09 |
Dec09 |
Mar10 |
Jun10 |
Sep10 |
Dec10 |
Mar11 |
Jun11 |
Sep11 |
| Price-to-Operating-Cash-Flow |
Get a 7-Day Free Trial
|
|
|
|
|
|
|
|
|
|
|
|
|
- |
- |
9.00 |
8.45 |
8.33 |
Competitive Comparison of Bioject Medical Technologies's Price-to-Operating-Cash-Flow
For the Medical Instruments & Supplies subindustry, Bioject Medical Technologies's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bioject Medical Technologies's Price-to-Operating-Cash-Flow Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Bioject Medical Technologies's Price-to-Operating-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Bioject Medical Technologies's Price-to-Operating-Cash-Flow falls into.
Bioject Medical Technologies Price-to-Operating-Cash-Flow Calculation
Bioject Medical Technologies's Price-to-Operating-Cash-Flow ratio for today is calculated as
| Price-to-Operating-Cash-Flow Ratio | = | Share Price | / | Cash Flow from Operations per share (TTM) |
| = | 0.0001 | / | 0.025 |
| = | 0.00 |
Bioject Medical Technologies's Share Price of today is $0.0001.
Bioject Medical Technologies's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Sep. 2011 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.03.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: Cash Flow from Operations per share is calculated as Cash Flow from Operations divided by Shares Outstanding (Diluted Average).
It can also be calculated from the numbers for the whole company:
Bioject Medical Technologies (Bioject Medical Technologies) Business Description
Traded in Other Exchanges
N/A
Address
Bioject Medical Technologies Inc commenced operations in 1985 and is a developer and manufacturer of needle-free injection therapy systems (NFITS). The Companys long-term goal is to become supplier of needle-free injection systems to the pharmaceutical and biotechnology industries. It focused its business development efforts on new and existing licensing and supply agreements with pharmaceutical and biotechnology companies, as well as numerous research agreements that could guide to long-term agreements. The Companys pipeline of prospective new partnerships remains active. It is also actively pursuing additional opportunities both domestically and overseas as it expands its current product line. The Companys Biojector 2000 system (B2000) consists of two components: a hand-held, reusable jet injector and a sterile, single-use, disposable plastic syringe capable of delivering variable doses of medication up to 1.0 mL. Drug Reconstitution System - The needle-free drug reconstitution system allows for the transfer of diluents to reconstitute powdered medications into liquid form and withdrawal of liquid medication into a syringe without the use of a needle. Vitajet - The Vitajet is also composed of two components, a portable injector unit and a disposable syringe. It is smaller and lower in cost than other products in its needle-free offering. ZetaJet - The ZetaJet is Biojects latest advance in needle-free delivery systems. It consists of two components, the portable injector and an auto-disabling disposable syringe. The medical equipment market is very competitive. Bioject Medical Technologies has two patents: Biojector 2000 and Vitajet. The Companys products and manufacturing operations are subject to extensive government regulations, both in the U.S. and abroad. In the U.S., the Food and Drug Administration (FDA) administers the Federal Food, Drug and Cosmetic Act (FFDCA) and has adopted regulations to administer the FFDCA.
Executives
| James C Gale |
director |
152 W 57TH STREET, 19TH FLOOR, NEW YORK NY 10019 |
| Sanders Morris Harris Inc/fa |
10 percent owner, other: See General Remarks |
600 TRAVIS, SUITE 5900, HOUSTON TX 77002 |
| David S Tierney |
director |
C/O ABLE LABORATORIES, INC., 6 HOLLYWOOD COURT, CN 1013, SOUTH PLAINFIELD NJ 07080 |
| Edward L Flynn |
director, 10 percent owner |
211 SOMERVILLE ROAD RTE 202N, BEDMINISTER NJ 07921 |
| Life Sciences Opportunities Fund Ii Lp |
10 percent owner |
152 W 57TH STREET 19TH FLOOR NEW YORK NY 10019 |
| Lof Partners Llc |
other: See general remarks |
152 W 57TH STREET 19TH FLOOR NEW YORK NY 10019 |
| Life Sciences Opportunities Fund Instittutional Ii Lp |
10 percent owner |
152 W 57TH STREET 19TH FLOOR NEW YORK NY 10019 |
| Randal D Chase |
director |
28 GEORGIA COURT, RICHMOND HILL A6 L4E ON7 |
| Brigid Makes |
director |
20245 SW 95TH AVENUE, TUALATIN OR 97062 |
| J Michael Redmond |
officer: Sr. VP Bus Dev. |
10 CANTERBURY ROAD, WINDHAM NH 03087 |
| Elan Corp Plc |
10 percent owner |
TREASURY BUILDING, LOWER GRAND CANAL STREET, DUBLIN 2 L2 00000 |
| Elan International Services Ltd |
10 percent owner |
C/O TREASURY BUILDING, LOWER GRAND CANAL STREET, DUBLIN L2 2 |
| Elan Pharmaceutical Investments Ltd |
10 percent owner |
102 ST JAMES COURT, FIETSS SMITH FL BERM D0 9999999999 |
| John P Gandolfo |
officer: CFO |
62 TERRACE ROAD, WAYNE NJ 07470 |
| Grace K Fey |
director |
1210 CROMWELL ROAD, HALIFAX NOVA SCOTIA A5 B3H4L2 |
Bioject Medical Technologies (Bioject Medical Technologies) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
BJCT has been successfully added to your